**Point Prevalence Surveys of Health Care Associated Infections: A Systematic Review**

Zikria Saleem1,2, Brian Godman3,4,5, Mohamed Azmi Hassali1, Furqan Khurshid Hashmi6, Faiza Azhar6, Inayat Ur Rehman 7,8

1 School of Pharmaceutical Sciences, Universiti Sains Malaysia, Malaysia

2 Rashid Latif College of Pharmacy, Pakistan

3Department of Clinical Pharmacology, Karolinska Institute, Stockholm, Sweden

4 Strathclyde Institute of Pharmacy and Biomedical Sciences, Strathclyde University,Glasgow, UK

5 Health Economics Centre, University of Liverpool Management School, Liverpool, UK

6 University College of Pharmacy, University of the Punjab, Lahore, Pakistan

7School of Pharmacy, Monash University Malaysia, Bandar Sunway

8Department of Pharmacy, Abdul Wali Khan University Mardan, Pakistan

**Corresponding Author**

Zikria Saleem**;** School of Pharmaceutical Sciences, Universiti Sains Malaysia, Malaysia**.** Email ID: xikria@gmail.com

(Accepted for publication Pathogens and Global Health – Please keep Confidential)

**Abstract**

Healthcare associated infections (HAIs) are considered as a serious public health issues that contribute substantially to the global burden of mortality and morbidity with respect to infectious diseases. The aim is to assess the burden of healthcare associated infections by collation of available data from published point prevalence surveys (PPS) on HAIs to give future guidance. Study protocol and methodology was designed according to preferred reporting items for systematic reviewsand meta-analysis (PRISMA) guidelines. Published research papers that conducted point prevalence survey of HAIs in hospital settings by following the structured survey methodology employed by European Centre of Disease Prevention and Control (ECDC) were included. Of 1212 articles, 67 studies were included in the final analysis conducted across different countries. Overall, 35 studies were conducted in Europe, 21 in Asia, 9 in America, and 2 in Africa. The highest prevalence of HAIs was recorded in a study conducted in adult ICU settings of 75 regions of Europe (51.3%). The majority of the studies included HAI data on urinary tract infections, respiratory tract infections and bloodstream infections. *Klebseilla pneumonia*, *Pseudomonas aeruginosa* and *E. coli* were the most frequent pathogens responsible for HAIs. PPS is useful tool to quantify HAIs and provides a robust baseline data for policy makers. However, a standardize surveillance method is required. In order to minimize the burden of HAIs, infection prevention and control programs and antibiotic stewardship may be effective strategies to minimize risk of HAIs.

Keywords: Point prevalence surveys, Healthcare associated infections, Hospital, Infection presentation and control.

**1. INTRODUCTION**

Globally, healthcare-associated infections (HAIs) are considered as a major health and economic burden, with a resultant increase in the length of hospitalization, morbidity and mortality amongst hospitalized patients [[1-4](#_ENREF_1)]. Overall, HAIs are considered as the most adverse event in healthcare delivery [[5](#_ENREF_5)]. Surveillance of HAIs is an integral component of any comprehensive infection prevention and control (IPC) program, which provides information that are necessary to highlight and address challenging areas [[6-9](#_ENREF_6)]. Point-prevalence surveys (PPS) have been used for the surveillance of HAI for many years [[10](#_ENREF_10)]. The pioneering project started in the 1970s by the US Centers for Disease Control and Prevention (CDC) who used repeated PPS to investigate the advantage of establishing IPC teams in US hospitals [[6](#_ENREF_6)]. In Europe, HAI surveillance and infection prevention and control programs are coordinated by the European Centre for Disease Prevention and Control (ECDC). PPS is a time and cost effective method which estimates the burden of HAIs and related risk factors, especially in hospitals with limited resources [[11-14](#_ENREF_11)]. However going forward, a more resource demanding and cumbersome program, i.e., prospective incidence surveillance, may be needed especially in high-risk specialties to help prevent HAIs [[15](#_ENREF_15), [16](#_ENREF_16)].

Whilst the exact global burden of HAI is unknown, estimated prevalence rates are between 5.7%-19.1% among low and middle income countries (LMICs) and 5.7% - 7.5% in high income countries [[17](#_ENREF_17), [18](#_ENREF_18)]. However, rates up to 28% to 45.8% have been reported in sub-Saharan African countries depending on the country and the ward surveyed [[19](#_ENREF_19), [20](#_ENREF_20)]. In 2002, the Centers for Disease Control and Prevention (CDC) reported approximately 1.7 million cases of HAIs in US hospitals [[21](#_ENREF_21)]. In 2012, a literature review performed by ECDC documented that over 3.2 million patients acquire at least one HAI in Europe every year with 16 million extra days of hospitalization and 37,000 attributable deaths [[22](#_ENREF_22)]. The revised European Annual Epidemiological Report (AER) published in 2008 reported that the overall annual burden of direct annual financial losses due to HAIs were estimated at approximately €7 billion [[22-24](#_ENREF_22)]. IPC strategies provide cost-effective solutions as 20–30 % of HAI are avoidable [[25](#_ENREF_25), [26](#_ENREF_26)]. However, as mentioned, the risks of HAIs appear considerably higher in LMICs including sub-Sahara Africa, and the impact on patients and health-care systems is considerable and typically greatly under estimated [[19](#_ENREF_19), [20](#_ENREF_20), [27-29](#_ENREF_27)]. This is a concern as HAIs increase the costs of patient care including additional diagnostic tests and therapies, prolonged hospitalization and post-discharge complications [[30](#_ENREF_30), [31](#_ENREF_31)]. Higher rates of HAIs in LMICs are enhanced by issues such as poor hand hygiene due for instance to heavy workloads, issues with infrastructure including a lack of water and blocked and leaking sinks, as well as poorly positioned facilities [[32](#_ENREF_32)].

Overall HAIs have an appreciable impact on patients, healthcare workers, healthcare practitioner, and national healthcare systems. Descriptive surveys remained a useful tool for assessing healthcare settings and might be helpful in interpreting major issues associated with patient care [[33](#_ENREF_33)]. Despite recent systematic and other reviews concerning HAIs among LMICs including sub-Sahara African countries [[4](#_ENREF_4), [19](#_ENREF_19), [20](#_ENREF_20), [29](#_ENREF_29), [34](#_ENREF_34)], we believe there is still an epidemiological gap because few resource-limited settings have accurate surveillance systems for monitoring HAIs, although this is improving [[9](#_ENREF_9)]. This is important given the high rate of infectious diseases in LMICs including sub-Sahara Africa with its high rate of HIV, TB and malaria, misuse of antibiotics in hospitals and variable prevention strategies [[32](#_ENREF_32), [35-38](#_ENREF_35)]. Consequently, in order to provide a current summary on the prevalence of HAIs, we undertook an updated systematic review to assess the prevalence of HAIs based on PPS, and to identify the type of infections and microorganisms responsible for HAIs to improve future care. This builds on our recent publication that reports high rates of HAIs in Pakistan [[39](#_ENREF_39)]. This systematic review gathers evidences concerning the burden of HAI in both LMIC and HIC, which we hope will help decision makers and officials to develop a robust system to cope up with HAIs by investigating constraints linked to the surveillance of HAIs in healthcare settings as well as identify opportunities for improvement.

**2. METHODS**

A systematic review was conducted to explore point prevalence surveys for HAIs. The study protocol and methodology was designed according to preferred reporting items for systematic and meta-analysis (PRISMA) guidelines [[40](#_ENREF_40)]. We aimed to detect point prevalence surveys worldwide focusing on the types of infections as well as microorganisms responsible for these various infections.

2.1 Data Sources

We retrieved relevant articles using PubMed, EBSCO, ProQuest, CINHAL and Scopus databases and published in English from 1995 to the present year (2019). A comprehensive grey literature review was also performed using Google Scholar, the World Health Organization and the website of the European Centre for Disease Prevention and Control in case we missed important references. The selected reference lists were subsequently analyzed. References of the selected articles were also retrieved and reviewed to again see if we had missed relevant articles from our initial search.

2.2 Search Strategy

Data were searched using the keywords “health-care associated infection”, “hospital-acquired infections”, “point prevalence”, “repeated prevalence”, “period prevalence”, “survey”, “hospital(s)”, “intensive care units” by using truncations and Boolean operators (“OR” “AND”) from 1995 until April 2018. The corresponding Medical Subject Heading (MeSH) terms for the above keywords were also tried. Abstracts and full-text articles were screened for eligibility by applying PICO (population, interventions, comparison, and outcomes) approach [[40](#_ENREF_40)].

2.3 Inclusion and Exclusion Criteria

In this systematic review, there was no restriction on the age or gender of the patients in the studies. We included English language abstracts and full-text articles on HAIs reporting three types of infections as well as three most frequent microorganisms responsible for HAIs. We excluded articles not in English. Review articles, editorials, case reports, qualitative studies, dissertations, as well as articles reporting the same information in a different format or Journal were also excluded. Studies lacking information about the types of infections were also excluded.

2.4 Quality Assessment

The methodological quality of included articles was assessed independently by two investigators (ZS and FA). For quality assessment of included articles, Newcastle-Ottawa scale (NOS) was used [[41-43](#_ENREF_41)]. This scale stratifies the methodological quality of papers into three subscales, i.e. selection, comparability and outcomes. Differences in assessments were debated and agreed following a discussion with the review authors (MAH and IR).

2.5 Data extraction

A data extraction form was developed. The items on the data extraction form were finalized after discussion amongst members of the research team. Extracted data included the authors, region, world bank ranking, settings, PPS methodology and protocol, population type, study duration, infected patients, most frequent types of infections and most frequent 3 types of microorganisms. Retrieved publications were subsequently filtered using the study inclusion and exclusion criteria by 2 independent reviewers. Data were extracted from eligible articles by assessing titles, abstracts, and full-text articles.

2.6 Outcomes

The primary outcomes of this review were to assess the world-wide prevalence of HAIs and to identify the types of infections and microorganism isolated responsible for HAIs. Such knowledge can be used to initiate pertinent activities in hospitals to improve the future management of patients in hospitals to reduce the prevalence of HAIs. The HAI case definitions were adopted from ECDC protocol [[13](#_ENREF_13)]. As a result, HAI was defined as ‘an infection occurring in a patient during the process of care in a hospital or other health care facility which was not present or incubating at the time of admission’. For the purposes of this protocol, an infection was defined as active on the day of the survey when: signs and symptoms were present on the date of the survey; OR signs and symptoms were no longer present but the patient was still receiving treatment for that infection on the date of the survey. An active infection was defined as healthcare-associated when: the onset of the signs and symptoms was on Day 3 of the current admission or later; OR the signs and symptoms of an active surgical site infection were present at admission or started before Day 3, and the surgical site infection occurred within 30 days of a surgical intervention.

**3. RESULTS**

3.1 Literature Research

The flow chart of the search and selection strategies of articles is illustrated in Figure 1. Through scientific and grey literature searches, after removal of duplicates (N=87), a total of 1212 articles were screened for eligibility. After screening, 290 articles were eligible for detailed assessment and the remaining articles not fulfilling the inclusion criteria (N=922) were excluded. Abstracts and full-text articles of 59 articles were not screened due to language restrictions; 87 articles did not provide sufficient data; 13 review articles were excluded and 64 articles did not mention the infection of interest. As a result, a total of 67 studies were subsequently included in the final analysis.

Insert Figure 1

The abstracts of these 67 studies, as well as full-text articles of point prevalence surveys of HAIs in adults and mixed populations, are summarized in Table 1, providing updated information on the type of infections and microorganisms. Table 2 summarizes the data on the pediatric population. Overall, 35 studies were conducted in Europe (33 studies on adults and 2 on pediatrics), 21 in Asia (19 studies on adults and 2 on pediatrics), 9 in America (5 studies on adults and 4 on pediatrics and 2 in Africa (adults), all reporting the proportion of overall HAIs in a mixed population of patients [[11-14](#_ENREF_11), [44-106](#_ENREF_44)]. The majority of point prevalence surveys were conducted in more than one hospital following the European Centre for Disease Control and Prevention (ECDC) protocol. Out of 21 studies conducted in Asia, six studies were undertaken in China [[12](#_ENREF_12), [76](#_ENREF_76), [79](#_ENREF_79), [80](#_ENREF_80), [84](#_ENREF_84), [85](#_ENREF_85)].

HAIs showed a higher prevalence in intensive care units compared to other wards. The highest prevalence of HAIs was recorded in a study conducted in adult ICU settings among 75 regions of Europe (51.3%) [[68](#_ENREF_68)]. In Asian countries, a study conducted in Turkey reported the highest prevalence rate of HAIs (48.7%) in ICU patients [[93](#_ENREF_93)]. Whereas, in case of complete hospital survey, the highest burden of HAIs was observed in one pediatric hospital of Russia (15.1%), followed by Ethiopia (14.8%) and Tunisia (14.3%). The HAI prevalence rate was 11.7% in North America [[99](#_ENREF_99), [106](#_ENREF_106)]. Gravel et al. performed a PPS among adult and pediatric patients separately in Canada showing a slightly higher prevalence rate of HAIs (10.4%) among adults in comparison to pediatric patients (8.0%) [[11](#_ENREF_11), [97](#_ENREF_97)]. A point prevalence study conducted in Ireland reported a higher HAI prevalence rate (4.3%) in long-term care facilities [[49](#_ENREF_49)].The lowest burden of HAIs was seen in a study conducted in six hospitals in Greece (2.9%).

3.2 Comparison of HAIs in HI and LMICs

Of the 67 selected studies, 46 studies were undertaken in high-income countries (HIs), 12 studies in upper middle-income countries (UMICs), 8 studies were conducted in LMICs and only one study in low-income countries (LICs) [[11-14](#_ENREF_11), [44-106](#_ENREF_44)]. All point prevalence surveys of HAIs in HIs have been published since 1995. 41 of 46 studies reported a prevalence rate of <20. In LMICs, point prevalence surveys of HAIs have been published since 2005. Of eight studies, five studies reported a prevalence rate of <10% and all except one reported prevalence rate of >20%. ICU acquired infections are the most common and leading HAIs hospital-wide. In LMICs, the prevalence rate of HAIs in ICU admitted patients is <35% while in HIs the prevalence of HAIs exceeds 50% [[65](#_ENREF_65), [68](#_ENREF_68), [75](#_ENREF_75), [81](#_ENREF_81), [103](#_ENREF_103)]. In our findings, the frequency of surgical site infections was significantly higher in LMICs when compared with the studies conducted in HIs [[44](#_ENREF_44), [61](#_ENREF_61), [73](#_ENREF_73), [83](#_ENREF_83)]. Acinetobacter species were responsible for HAIs in LMICs [[81](#_ENREF_81), [83](#_ENREF_83), [87](#_ENREF_87)]. In HIs, E. coli appeared to be the major cause of HAIs [[13](#_ENREF_13), [45](#_ENREF_45), [48](#_ENREF_48), [52](#_ENREF_52), [57](#_ENREF_57)].

3.3 Types of infections and microorganisms isolated in among pediatric patients

The majority of published studies emphasized more than one site of infection. Regarding the types of infections, the majority of studies included data on urinary tract infections, respiratory tract infections, bloodstream infections, and surgical site infections. Among European countries, blood-stream infections (52.6%) were one of the commonest types of infections among pediatric patient, followed by upper respiratory tract infections (45.0%) [[102](#_ENREF_102), [105](#_ENREF_105)]. Blood-stream infections (30.6%) in North America and pneumonia (65.2%) in Asia were the most frequent infections among pediatric patients [[94](#_ENREF_94), [103](#_ENREF_103)]. In the United States, *coagulase-negative Staphylococcus* (31.6% and 19.5%) was the major cause of HAIs, followed by *Enterococcus species* (10.3% and 12.2%) [[104](#_ENREF_104), [105](#_ENREF_105)]. *Klebsiella pneumonia*, *Pseudomonasaeroginosa*,and*Acinetobacter* species were the most frequent pathogens responsible for HAIs among Asian countries [[14](#_ENREF_14), [103](#_ENREF_103)].

3.4 Types of infections and microorganisms isolated in adults

In Africa, surgical site infections (51.1%) were the most frequent type of infection [[99](#_ENREF_99)]. In Vietnam, there were high reported rates of lower respiratory tract infections in adults (79.4%), whereas in Italy reported high rates of bloodstream infections (50.0%) [[55](#_ENREF_55), [81](#_ENREF_81)]. Respiratory tract infections were the most frequent type of infections in patients admitted to ICUs (63.5%) and in patients admitted to long-term care facilities in Ireland (35.0%) [[49](#_ENREF_49), [68](#_ENREF_68)].

More than half of the HAIs infections are caused by gram-negative bacteria. Gram-negative pathogens such as *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *E. coli*, and *Acinetobacte*r species were the most frequently reported pathogens. Gram-positive pathogens such as *Staphylococcus aureus* and *clostridium difficile* were also included in these studies. *Staphylococcus aureus*, *Pseudomonas aeroginosa*, and *Klebsiella* species were the major cause of HAIs in Africa (20.4%, 18.3% and 22.4%) and South America the (21.6%, 12.5% and 19.2%) [[98](#_ENREF_98), [99](#_ENREF_99)].Gram-negative bacteria were responsible for the different types of healthcare-associated infections in European countries (52.7%) as well as in Asian countries (67.1%) [[67](#_ENREF_67), [80](#_ENREF_80)]. In ICUs patients, *AcinetobacterBaumannii* (24.4%) was the most common pathogen responsible for HAIs [[81](#_ENREF_81)]. Other publications reporting types of infections as well as types of microorganism are listed in Tables 1 and 2.

Insert Tables 1 and 2.

3.5 Quality Assessment

The maximum of ten stars is awarded to a study. We considered study a high quality when scored >7, a medium quality scored 5-6 and a low quality scored 0-4. The stars that were awarded to studies ranged from six to nine, and the average value was 7.7 (Table 3). Most of the studies used ECDC protocol as a validated measurement tool to assess the prevalence of HAIs. Independent blind assessment was done in all studies.

Insert Table 3

**4. DISCUSSION**

Healthcare-associated infections are among the most serious public health issues with substantial morbidity, mortality and costs [[3](#_ENREF_3), [20](#_ENREF_20), [107](#_ENREF_107), [108](#_ENREF_108)]. We subsequently systematically reviewed sixty-seven studies reporting the proportion of overall HAIs in mixed patient populations. The selected studies conducted in various healthcare settings provide baseline information in order to develop future intervention research. Because of multi-factorial features of HAIs, healthcare settings are challenging domains in order to identify the various types of infections and microorganisms, especially in LMICs. Most of the studies were conducted in Europe and Asia. Two studies were conducted in Africa, one in Ethiopia and one in Tunisia. Previous literature surveys reported that HAIs remained a public health problem in LMICs compared with developed countries [[29](#_ENREF_29)]. However, to date limited studies regarding PPS of HAIs have been performed in LMICs because of lack of national surveillance systems. The main reasons for this may include a lack of human and financial resources, the absence of expertise in interpretation of the data, the paucity of reliable diagnostic procedures, the scarcity of data obtained from patient records and the absence of software used for surveillance of HAIs [[17](#_ENREF_17)].

In Canada, Denis et al conducted prevalence surveys in both adults and pediatric settings with reportedly a high prevalence rate of HAIs in adults than in pediatric patients. One of the studies reported a 3-20 times higher neonatal infection rate in developing countries compared to developed countries [[28](#_ENREF_28)]. Rezende and colleagues performed a prevalence survey in Brazil and reported 11.4% prevalence of HAIs, requiring inter-institutional efforts so that appropriate measures could be taken. The frequency of endemic HAIs in neonatal ICUs in a few regions for example Brazil is 9 times higher than in USA [[29](#_ENREF_29)]. The higher heterogeneity in the prevalence data may be due to the different study design and the selection of participants, e.g., study populations, races, and sample sizes, among the reviewed studies. According to the WHO, the pooled prevalence of HAIs in LMICs was 10.1%, while in HIs the pooled prevalence of HAIs was 7.6% [[34](#_ENREF_34)]. Due to insufficient data or lack of resources in LMICs, the pooled prevalence of HAIs was significantly higher in LMICs than in HIs.

Our findings indicated that lower respiratory tract infections are the leading HAIs followed by urinary tract infections, surgical site infections and bloodstream infections in most of the selected studies. A study performed in Australia reported high rates of illness from acute as well as chronic respiratory tract infections in the indigenous pediatric population [[109](#_ENREF_109)]. This is important as pneumonia is the most frequent lower respiratory tract infection and a leading cause of death [[110](#_ENREF_110)]. A study conducted in Ethiopia has reported high rates of surgical site infections. Surgical site infection leads to a prolonged hospital stay and increased costs of therapy [[111](#_ENREF_111)]. In our findings, surgical site infections were the most frequent type of HAI in LMICs. This is similar to Allegranzi and his colleagues and the WHO who also reported surgical site infection as the most common type of HAI [[17](#_ENREF_17), [34](#_ENREF_34)]. Surgery and invasive procedures were among the significant risk factors responsible for surgical site infections (SSIs) [[112](#_ENREF_112)]. To address concerns, the WHO have published their guidelines to ensure surgical patient’s safety which includes a safety checklist to reduce mortality from SSIs [[113](#_ENREF_113)].

The evaluation of microbiological patterns of HAIs was based on isolates of the three most frequent microorganisms. Gram-negative bacteria were reported as the principal causative pathogens in Europe and Asia [[48](#_ENREF_48), [57](#_ENREF_57), [70](#_ENREF_70), [80](#_ENREF_80), [91](#_ENREF_91), [93](#_ENREF_93)]. Our results reported that *Staphylococcus aureus*, *Pseudomonas aeroginosa*, and *Klebsiella* species were the most frequent pathogens in Africa and South America [[99](#_ENREF_99)]. This is similar to a review in Africa where *Klebsiella*,  *Staphylococcus aureus*, *Pseudomonas aeroginosa* and E coli were the most common organisms associated with healthcare-associated infections [[114](#_ENREF_114)]. Six point prevalence studies conducted in China reported *Pseudomonas aeruginosa* as the leading cause of healthcare-associated infections [[12](#_ENREF_12), [76](#_ENREF_76), [79](#_ENREF_79), [80](#_ENREF_80), [84](#_ENREF_84), [85](#_ENREF_85)].

Overall, we believe our data provides significant information to guide policy makers to identify risk factors of HAIs and to devise prior strategies to reduce HAIs. In order to detect trends of HAIs, additional point prevalence surveys are needed, with the findings directing quality improvement programmes in hospitals. As part of this, proper instruction should be given to patients to identify and report signs and symptoms of HAIs. This intervention may help in the identification of HAIs during their hospital stay and after discharge. Moreover, prioritization of resources may help to prevent HAIs and improve patient’s safety once specific activities have been identified [[115](#_ENREF_115)]. Overall, patient participation is considered as an integral part of reducing medical error and improving patient’s safety [[116](#_ENREF_116)].We are aware that there will be different challenges to reduce HAIs between HIs and LMICs in line with the challenges to introduce effective antimicrobial stewardship programmes in LMICs and HIs [[117](#_ENREF_117)]. This especially given the current lack of AMS programmes among a number of LMICs [[118](#_ENREF_118), [119](#_ENREF_119)]. Consequently, quality improvement programmes to reduce future HAIs must be tailored to the given country and situation.

Our study has limitations that should be kept in mind when elucidating data from selected studies. The current systematic review utilized five databases with specific emphasis on terms describing point prevalence surveys of healthcare-associated infections and hospital-acquired infections. Limited grey literature searches were also performed using additional search terms that identified relevant articles. As a result, some relevant articles may have been missed. Moreover, only English language studies were retrieved resulting in the exclusion of studies in other languages. In some studies, available information was not explained enough such as lack of information on microorganisms. In other studies, the analysis performed by the authors was a mixture of HAI prevalence data on both intensive and acute care units. Considering higher HAI prevalence rates in intensive care units, it could influence the differences in results. Another limitation is that lower reported HA prevalence does not necessarily or even often mean lower true prevalence rates - overall diagnostic capabilities and reporting culture can play a surprisingly large role between countries and cultures, leading to large differences which can be misinterpreted. The difference in the quality of different countries’ health-care systems and the definitions of infections had also a discernible influence on the systematic review. Lastly, we had divided studies into adults and pediatric population by considering total hospital population as adults. However, despite these limitations we believe our findings are robust providing direction to others.

**5. CONCLUSION**

The current systematic review provides an updated synthesis of literature concerning the overall burden of HAIs. These findings reported the existence of multiple pathogens responsible for healthcare associated infections in a variety of healthcare settings. Based on this literature review, standardized surveillance systems, infection prevention and control programs, multidisciplinary teams, instigation of antibiotic stewardship programmes, as well as the raising of awareness among medical staff and policy makers regarding HAIs and ways to prevent these may be effective strategies to minimize the future risk of HAIs. We recommend that more point prevalence surveys should be conducted in order to identify and target scarce resources for the prevention of future HAIs in all countries especially LMICs building on ongoing activities in these countries.

Funding resources: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of Interests: None.

**REFERENCES**

1. Stone, P.W., D. Braccia, and E. Larson, *Systematic review of economic analyses of health care-associated infections.* American journal of infection control, 2005. **33**(9): p. 501-509.

2. Burke, J.P., *Infection control--a problem for patient safety.* The New England journal of medicine, 2003. **348**(7): p. 651.

3. Manoukian, S., et al., *Estimating excess length of stay due to healthcare-associated infections: a systematic review and meta-analysis of statistical methodology.* Journal of Hospital Infection, 2018.

4. Irek, E.O., et al., *A systematic review of healthcare-associated infections in Africa: An antimicrobial resistance perspective.* Afr J Lab Med, 2018. **7**(2): p. 796.

5. (WHO), W.H.O., *Health Care-associated infections. FACT SHEET.* 2014.

6. Haley, R.W., et al., *The efficacy oe infection surveillance and control programs in preventing nosocomial infections in us hospitals.* American journal of epidemiology, 1985. **121**(2): p. 182-205.

7. Morton, A., *Hospital safety and hospital acquired infection.* Healthcare Infection, 2006. **11**(1): p. 3-5.

8. Reilly, J., et al., *Evidence-based infection control planning based on national healthcare-associated infection prevalence data.* Infection Control & Hospital Epidemiology, 2009. **30**(2): p. 187-189.

9. Talaat, M., et al., *National surveillance of health care–associated infections in Egypt: developing a sustainable program in a resource-limited country.* American journal of infection control, 2016. **44**(11): p. 1296-1301.

10. Zingg, W., et al., *Assessing the Burden of Healthcare-Associated Infections through Prevalence Studies: What Is the Best Method? 1.* Infection Control & Hospital Epidemiology, 2014. **35**(6): p. 674-684.

11. Gravel, D., et al., *A point prevalence survey of health care–associated infections in pediatric populations in major Canadian acute care hospitals.* American journal of infection control, 2007. **35**(3): p. 157-162.

12. Xie, D.-s., et al., *Point prevalence surveys of healthcare-associated infection in 13 hospitals in Hubei Province, China, 2007–2008.* Journal of Hospital Infection, 2010. **76**(2): p. 150-155.

13. Zarb, P., et al., *The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use.* Euro Surveill, 2012. **17**(46): p. 20316.

14. Kepenekli, E., et al., *A national point-prevalence survey of pediatric intensive care unit-acquired, healthcare-associated infections in Turkey.* Japanese Journal of Infectious Diseases, 2015: p. JJID. 2014.385.

15. Glenister, H., *Sensitivity and specificity of surveillance methods.* BAILLIERES CLINICAL INFECTIOUS DISEASES, 1996. **3**(2): p. 197-210.

16. Geffers, C., et al., *Incidence of healthcare-associated infections in high-risk neonates: results from the German surveillance system for very-low-birthweight infants.* Journal of Hospital Infection, 2008. **68**(3): p. 214-221.

17. Allegranzi, B., et al., *Report on the burden of endemic health care-associated infection worldwide.* Geneva, Switzerland: World Health Organization, 2011.

18. Prevention, E.C.f.D., et al., *Point Prevalence Survey of Healthcare-associated Infections and Antimicrobial Use in European Acute Care Hospitals: 2011-2012*. 2013: Publications Office of the European Union.

19. Nejad, S.B., et al., *Health-care-associated infection in Africa: a systematic review.* Bulletin of the World Health Organization, 2011. **89**: p. 757-765.

20. Rothe, C., C. Schlaich, and S. Thompson, *Healthcare-associated infections in sub-Saharan Africa.* Journal of Hospital Infection, 2013. **85**(4): p. 257-267.

21. Klevens, R.M., et al., *Estimating health care-associated infections and deaths in US hospitals, 2002.* Public health reports, 2007. **122**(2): p. 160-166.

22. ECDC, *Economic evaluations of interventions to prevent healthcare-associated infections: Literature Review.* 2017.

23. Amato-Gauci, A., *Annual Epidemiological Report on Communicable Diseases in Europe: Report on the status of communicable diseases in the EU and EEA/EFTA countries*. 2007: European Centre for Disease Prevention and Control.

24. Control, E.C.f.D.P.a., *Annual Epidemiological Report on Communicable Diseases in Europe.* 2008.

25. Umscheid, C.A., et al., *Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs.* Infection Control & Hospital Epidemiology, 2011. **32**(2): p. 101-114.

26. Harbarth, S., H. Sax, and P. Gastmeier, *The preventable proportion of nosocomial infections: an overview of published reports.* Journal of Hospital infection, 2003. **54**(4): p. 258-266.

27. Rosenthal, V.D., D.G. Maki, and N. Graves, *The International Nosocomial Infection Control Consortium (INICC): goals and objectives, description of surveillance methods, and operational activities.* American journal of infection control, 2008. **36**(9): p. e1-e12.

28. Zaidi, A.K., et al., *Hospital-acquired neonatal infections in developing countries.* The Lancet, 2005. **365**(9465): p. 1175-1188.

29. Allegranzi, B., et al., *Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis.* The Lancet, 2011. **377**(9761): p. 228-241.

30. De Angelis, G., et al., *Estimating the impact of healthcare-associated infections on length of stay and costs.* Clinical microbiology and infection, 2010. **16**(12): p. 1729-1735.

31. Graves, N., *Economics and preventing hospital-acquired infection.* Emerging infectious diseases, 2004. **10**(4): p. 561.

32. Ataiyero, Y., J. Dyson, and M. Graham, *Barriers to hand hygiene practices among health care workers in sub-Saharan African countries: A narrative review.* American Journal of Infection Control, 2018.

33. Charrier, L., et al., *Surveillance of healthcare-associated infections in Piemonte, Italy: results from a second regional prevalence study.* BMC public health, 2014. **14**(1): p. 558.

34. Organization, W.H., *Report on the burden of endemic health care-associated infection worldwide.* 2011.

35. Sahiledengle, B., *Stethoscope disinfection is rarely done in Ethiopia: what are the associated factors?* bioRxiv, 2018: p. 474098.

36. Tiroyakgosi, C., et al., *Ongoing initiatives to improve the use of antibiotics in Botswana: University of Botswana symposium meeting report.* Expert review of anti-infective therapy, 2018. **16**(5): p. 381-384.

37. Mwita, J.C., et al., *Prophylactic antibiotics to prevent surgical site infections in Botswana: findings and implications.* Hospital Practice, 2018: p. 1-6.

38. Organization, W.H., *Use of high burden country lists for TB by WHO in the post-2015 era.* Geneva: World Health Organization, 2015.

39. Saleem, Z., et al., *A multicenter point prevalence survey of health care–associated infections in Pakistan: Findings and implications.* American journal of infection control, 2018.

40. Moher, D., et al., *Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.* Systematic reviews, 2015. **4**(1): p. 1.

41. Wells, G., et al., *Newcastle-Ottawa quality assessment scale.* Ottawa Hospital Research Institute, 2013.

42. Modesti, P.A., et al., *Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis.* PLoS One, 2016. **11**(1): p. e0147601.

43. Silva, T.B., et al., *Effectiveness and safety of insulin glargine versus detemir analysis in patients with type 1 diabetes: systematic review and meta-analysis.* Therapeutic advances in endocrinology and metabolism, 2018. **9**(8): p. 241-254.

44. Deptuła, A., et al., *Prevalence of healthcare-associated infections in Polish adult intensive care units: summary data from the ECDC European Point Prevalence Survey of Hospital-associated Infections and Antimicrobial Use in Poland 2012–2014.* Journal of Hospital Infection, 2017. **96**(2): p. 145-150.

45. Sticchi, C., et al., *Regional point prevalence study of healthcare-associated infections and antimicrobial use in acute care hospitals in Liguria, Italy.* Journal of Hospital Infection, 2017.

46. Swissnoso, *Point Prevalence Survey of healthcare-associated infections and antimicrobial use in Swiss acute care hospital 2017.* 2017.

47. Klavs, I., et al., *The prevalence of and risk factors for healthcare-associated infections in Slovenia: results of the second national survey.* Slovenian Journal of Public Health, 2016. **55**(4): p. 239-247.

48. Lusignani, L.S., et al., *A national point prevalence study on healthcare-associated infections and antimicrobial use in Austria.* Wiener klinische Wochenschrift, 2016. **128**(3-4): p. 89-94.

49. Roche, F., S. Donlon, and K. Burns, *Point prevalence survey of healthcare-associated infections and use of antimicrobials in Irish intellectual disability long-term care facilities: 2013.* Journal of Hospital Infection, 2016. **93**(4): p. 410-417.

50. Stefkovicova, M., I. Rovny, and J. Brnova, *Point prevalence survey of healthcare-associated infections in Slovakia: from zero to real data.* Antimicrobial resistance and infection control, 2015. **4**(1): p. P277.

51. Miliani, K., et al., *National point prevalence survey of healthcare-associated infections and antimicrobial use in French home care settings, May to June 2012.* Eurosurveillance, 2015. **20**(27): p. 21182.

52. katrien Latour, B.C.B.J., Maria Luisa, , *PPS of healthcare-associated infections and antimicrobial use in European long-term care facilities.* 2014.

53. Katrien Latour, P.k., Maria Luisa, *Point prevalence survey of healthcare-associated infections and antimicrobial use in European long-term care facilities, 2013.* 2014.

54. Erdem, H., et al., *Surveillance, control and management of infections in intensive care units in Southern Europe, Turkey and Iran–a prospective multicenter point prevalence study.* Journal of Infection, 2014. **68**(2): p. 131-140.

55. Sinatra, I., et al., *Prevalence survey of healthcare-associated infections and antimicrobial use at the University Hospital" Paolo Giaccone", Palermo, Italy.* Journal of preventive medicine and hygiene, 2013. **54**(4): p. 200.

56. Smiddy, M.P. and O.M. Murphy, *The use of point prevalence surveys of healthcare-associated infection to identify risk factors and facilitate infection prevention and control planning.* Healthcare infection, 2013. **18**(4): p. 162-167.

57. Behnke, M., et al., *Nosocomial infection and antibiotic use: a second national prevalence study in Germany.* Deutsches Ärzteblatt International, 2013. **110**(38): p. 627.

58. Carl Suetens, S.H., Jana Kolman, *Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals 2011-2012.* 2013.

59. Heudorf, U., K. Boehlcke, and M. Schade, *Healthcare-associated infections in long-term care facilities (HALT) in Frankfurt am Main, Germany, January to March 2011.* Euro Surveill, 2012. **17**(35): p. 5-11.

60. Coello, R., et al., *Prevalence of healthcare device-associated infection using point prevalence surveys of antimicrobial prescribing and existing electronic data.* Journal of Hospital Infection, 2011. **78**(4): p. 264-268.

61. Lietard, C., et al., *NATIONAL POINT PREVALENCE SURVEY OF HEALTHCARE‐ASSOCIATED INFECTIONS: RESULTS FOR PEOPLE AGED 65 AND OLDER, FRANCE, 2006.* Journal of the American Geriatrics Society, 2011. **59**(4): p. 763-765.

62. Alexopoulos, E.C., et al., *Wide range of point prevalences of healthcare-associated infections in Western Greece.* Epidemiology & Infection, 2011. **139**(11): p. 1734-1739.

63. Hopkins, S., K. Shaw, and L. Simpson, *English national point prevalence survey on healthcare-associated infections and antimicrobial use.* London (United Kingdom): Health ProtectionAgency, 2011.

64. Cairns, S., et al., *The Prevalence of Health Care–Associated Infection in Older People in Acute Care Hospitals.* Infection Control & Hospital Epidemiology, 2011. **32**(8): p. 763-767.

65. Cairns, S., J. Reilly, and M. Booth, *Prevalence of healthcare-associated infection in Scottish intensive care units.* Journal of Hospital Infection, 2010. **76**(4): p. 308-310.

66. Gordts, B., et al., *The 2007 Belgian national prevalence survey for hospital-acquired infections.* Journal of Hospital Infection, 2010. **75**(3): p. 163-167.

67. Lanini, S., et al., *Healthcare-Associated Infection in Italy Annual Point-Prevalence Surveys, 2002–2004.* Infection Control & Hospital Epidemiology, 2009. **30**(7): p. 659-665.

68. Vincent, J.-L., et al., *International study of the prevalence and outcomes of infection in intensive care units.* Jama, 2009. **302**(21): p. 2323-2329.

69. Patte, R., et al., *Prevalence of hospital-acquired infections in a home care setting.* Journal of Hospital Infection, 2005. **59**(2): p. 148-151.

70. Lizioli, A., et al., *Prevalence of nosocomial infections in Italy: result from the Lombardy survey in 2000.* Journal of Hospital Infection, 2003. **54**(2): p. 141-148.

71. Starakis, I., et al., *Repeated point prevalence survey of nosocomial infections in a Greek university hospital.* Journal of chemotherapy, 2002. **14**(3): p. 272-278.

72. Gikas, A., et al., *Prevalence study of hospital-acquired infections in 14 Greek hospitals: planning from the local to the national surveillance level.* Journal of hospital infection, 2002. **50**(4): p. 269-275.

73. Group, F.P.S.S., *Prevalence of nosocomial infections in France: results of the nationwide survey in 1996.* Journal of Hospital Infection, 2000. **46**(3): p. 186-193.

74. Pittet, D., et al., *Prevalence and risk factors for nosocomial infections in four university hospitals in Switzerland.* Infection Control & Hospital Epidemiology, 1999. **20**(1): p. 37-42.

75. Vincent, J.-L., et al., *The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) Study.* Jama, 1995. **274**(8): p. 639-644.

76. Chen, Y., et al., *A point-prevalence survey of healthcare-associated infection in fifty-two Chinese hospitals.* Journal of Hospital Infection, 2017. **95**(1): p. 105-111.

77. Nair, V., et al., *Point prevalence & risk factor assessment for hospital-acquired infections in a tertiary care hospital in Pune, India.* The Indian journal of medical research, 2017. **145**(6): p. 824.

78. Cai, Y., et al., *Prevalence of healthcare-associated infections and antimicrobial use among adult inpatients in Singapore acute-care hospitals: results from the first national point prevalence survey.* Clinical Infectious Diseases, 2017. **64**(suppl\_2): p. S61-S67.

79. Liu, J., et al., *Point-prevalence survey of healthcare-associated infections in Beijing, China: a survey and analysis in 2014.* Journal of Hospital Infection, 2016. **93**(3): p. 271-279.

80. Zhang, Y., et al., *Annual surveys for point-prevalence of healthcare-associated infection in a tertiary hospital in Beijing, China, 2012-2014.* BMC infectious diseases, 2016. **16**(1): p. 161.

81. Phu, V.D., et al., *Burden of hospital acquired infections and antimicrobial use in Vietnamese adult intensive care units.* PloS one, 2016. **11**(1): p. e0147544.

82. Morioka, H., et al., *The first point prevalence survey of health care–associated infection and antimicrobial use in a Japanese university hospital: A pilot study.* American journal of infection control, 2016. **44**(7): p. e119-e123.

83. Kumar, A., et al., *Point prevalence surveys of healthcare-associated infections and use of indwelling devices and antimicrobials over three years in a tertiary care hospital in India.* Journal of Hospital Infection, 2014. **86**(4): p. 272-274.

84. Tao, X.-B., et al., *Hospital-acquired infection rate in a tertiary care teaching hospital in China: a cross-sectional survey involving 2434 inpatients.* International Journal of Infectious Diseases, 2014. **27**: p. 7-9.

85. Xie, D.-s., et al., *Annual point-prevalence of healthcare-associated infection surveys in a university hospital in China, 2007–2011.* Journal of infection and public health, 2013. **6**(6): p. 416-422.

86. Askarian, M., M. Yadollahi, and O. Assadian, *Point prevalence and risk factors of hospital acquired infections in a cluster of university-affiliated hospitals in Shiraz, Iran.* Journal of infection and public health, 2012. **5**(2): p. 169-176.

87. Thu, T.A., et al., *A point-prevalence study on healthcare-associated infections in Vietnam: public health implications.* Infection Control & Hospital Epidemiology, 2011. **32**(10): p. 1039-1041.

88. Ider, B.-E., et al., *Prevalence of hospital-acquired infections and antibiotic use in two tertiary Mongolian hospitals.* Journal of Hospital Infection, 2010. **75**(3): p. 214-219.

89. Lee, M., et al., *Prevalence of hospital infection and antibiotic use at a university medical center in Hong Kong.* Journal of Hospital Infection, 2007. **65**(4): p. 341-347.

90. Balkhy, H.H., et al., *Hospital-and community-acquired infections: a point prevalence and risk factors survey in a tertiary care center in Saudi Arabia.* International journal of infectious diseases, 2006. **10**(4): p. 326-333.

91. Danchaivijitr, S., et al., *Prevalence and impacts of nosocomial infection in Thailand 2001.* J Med Assoc Thai, 2005. **88**(Suppl 10): p. S1-9.

92. Hughes, A.J., et al., *Prevalence of nosocomial infection and antibiotic use at a university medical center in Malaysia.* Infection Control & Hospital Epidemiology, 2005. **26**(1): p. 100-104.

93. Esen, S., H. Leblebicioglu, and S. Group, *Prevalence of nosocomial infections at intensive care units in Turkey: a multicentre 1-day point prevalence study.* Scandinavian journal of infectious diseases, 2004. **36**(2): p. 144-148.

94. Rutledge-Taylor, K., et al., *A point prevalence survey of health care-associated infections in Canadian pediatric inpatients.* American journal of infection control, 2012. **40**(6): p. 491-496.

95. Magill, S.S., et al., *Prevalence of healthcare-associated infections in acute care hospitals in Jacksonville, Florida.* Infection Control & Hospital Epidemiology, 2012. **33**(3): p. 283-291.

96. Magill, S.S., et al., *Multistate point-prevalence survey of health care–associated infections.* New England Journal of Medicine, 2014. **370**(13): p. 1198-1208.

97. Gravel, D., et al., *Point prevalence survey for healthcare-associated infections within Canadian adult acute-care hospitals.* Journal of Hospital Infection, 2007. **66**(3): p. 243-248.

98. Rezende, E.M., et al., *Prevalence of nosocomial infections in general hospitals in Belo Horizonte.* Infection Control & Hospital Epidemiology, 1998. **19**(11): p. 872-876.

99. Yallew, W.W., A. Kumie, and F.M. Yehuala, *Point prevalence of hospital-acquired infections in two teaching hospitals of Amhara region in Ethiopia.* Drug, healthcare and patient safety, 2016. **8**: p. 71.

100. Kallel, H., et al., *Prevalence of hospital-acquired infection in a Tunisian hospital.* Journal of Hospital Infection, 2005. **59**(4): p. 343-347.

101. Zingg, W., et al., *Health-care-associated infections in neonates, children, and adolescents: an analysis of paediatric data from the European Centre for Disease Prevention and Control point-prevalence survey.* The Lancet Infectious Diseases, 2017. **17**(4): p. 381-389.

102. Hajdu, A., et al., *A point prevalence survey of hospital-acquired infections and antimicrobial use in a paediatric hospital in north-western Russia.* Journal of Hospital Infection, 2007. **66**(4): p. 378-384.

103. Le, N.K., et al., *High prevalence of hospital-acquired infections caused by gram-negative carbapenem resistant strains in Vietnamese pediatric ICUs: A multi-centre point prevalence survey.* Medicine, 2016. **95**(27).

104. Grohskopf, L.A., et al., *A national point-prevalence survey of pediatric intensive care unit-acquired infections in the United States.* The Journal of pediatrics, 2002. **140**(4): p. 432-438.

105. Sohn, A.H., et al., *Prevalence of nosocomial infections in neonatal intensive care unit patients: results from the first national point-prevalence survey.* The Journal of pediatrics, 2001. **139**(6): p. 821-827.

106. Taylor, G., et al., *Assessing the magnitude and trends in hospital acquired infections in Canadian hospitals through sequential point prevalence surveys.* Antimicrobial Resistance & Infection Control, 2016. **5**(1): p. 19.

107. Manosuthi, W., et al., *HEALTHCARE-ASSOCIATED INFECTIONS AT SELECTED HOSPITALS IN THAILAND.* Southeast Asian Journal of Tropical Medicine and Public Health, 2017. **48**(1): p. 204-212.

108. Glance, L.G., et al., *Increases in mortality, length of stay, and cost associated with hospital-acquired infections in trauma patients.* Archives of surgery, 2011. **146**(7): p. 794-801.

109. Chang, A.B., et al., *Lower respiratory tract infections.* Pediatric Clinics, 2009. **56**(6): p. 1303-1321.

110. Troeger, C.E., et al., *Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017.* The Lancet Respiratory Medicine, 2018.

111. de Lissovoy, G., et al., *Surgical site infection: incidence and impact on hospital utilization and treatment costs.* American journal of infection control, 2009. **37**(5): p. 387-397.

112. Metintas, S., et al., *Prevalence and characteristics of nosocomial infections in a Turkish university hospital.* American journal of infection control, 2004. **32**(7): p. 409-413.

113. Haynes, A.B., et al., *A surgical safety checklist to reduce morbidity and mortality in a global population.* New England Journal of Medicine, 2009. **360**(5): p. 491-499.

114. Irek, E.O., et al., *A systematic review of healthcare-associated infections in Africa: An antimicrobial resistance perspective.* African journal of laboratory medicine, 2018. **7**(2): p. 1-9.

115. Durlach, R., et al., *Prevalence survey of healthcare-associated infections in Argentina; comparison with England, Wales, Northern Ireland and South Africa.* Journal of Hospital Infection, 2012. **80**(3): p. 217-223.

116. Longtin, Y., et al. *Patient participation: current knowledge and applicability to patient safety*. in *Mayo Clinic Proceedings*. 2010. Elsevier.

117. Cox, J., et al., *Antibiotic stewardship in low-and middle-income countries: the same but different?* Clinical Microbiology and Infection, 2017.

118. Fadare, J.O., et al., *Status of antimicrobial stewardship programmes in Nigerian tertiary healthcare facilities: Findings and implications.* Journal of global antimicrobial resistance, 2019. **17**: p. 132-136.

119. Kalungia, A.C., et al., *Antimicrobial stewardship knowledge and perception among physicians and pharmacists at leading tertiary teaching hospitals in Zambia: implications for future policy and practice.* Journal of Chemotherapy, 2019: p. 1-10.

|  |
| --- |
| **TABLE 1.** Point Prevalence Surveys in mixed population |
| **Continent and Countries** | **World** **Bank Classification** | **Author Name and Date** | **Settings** | **PPS Method** | **PPS Protocol** | **Study Duration** | **HAIs****(%)\*** | **Top Three Types of Infections****(%)\*** | **Top Three types of microorganisms****(%)** |
| **EUROPE** |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Poland [[44](#_ENREF_44)] | HI | Deptula et al., 2017 | 160 ICUs | Period | ECDC, EU-PPS & AU | 2012-2014 | 370/945(39.1%) | Respiratory tract infections(45%) | Bloodstream infections(14%) | Surgical site infections (13%) | Acinetobacter baumannii(15.2%) | Pseudomonas aeruginosa(14.1%) | Klebsiella pneumoniae(14.1%) |
| Italy [[45](#_ENREF_45)] | HI | Sticchi et al.,2017 | 18 hospitals | Period | ECDC | 22 March-22 April 2016 | 376/3647(10.3%) | Respiratory tract infections(21.7%) | Urinary tract infections (20.1%) | Bloodstream infections (16.8%) | E. coli(18.2%) | Klebseilla pneumonia(13.4%) | Coagulase negative staphylococcus(12.5%) |
| Switzerland [[46](#_ENREF_46)] | HI | Swissnoso, 2017 | 96 hospitals | Period | ECDC | April-May 2017 | 763/12931(5.9%) | Surgical site infections(29.0%) | Lower respiratory tract infections(18.0%) | Urinary tract infections(15.0%) | Enterobacteriaceae(45.7%) | Gram positive cocci(36.6%) | Gram negative bacteria(5.5%) |
| Slovenia [[47](#_ENREF_47)] | HI | Klavs et al., 2016 | 21 hospitals | One day | ECDC | October 2011 | 358/5628(6.3%) | Upper respiratory tract infections(21.5%) | Pneumonia(21.0%) | Surgical site infection(18.4%) | - | - | - |
| Austria [[48](#_ENREF_48)] | HI | Lusignani et al., 2016 | 9 hospitals | Period | ECDC | May- June 2012 | 268/4321(6.2%) | Urinary tract infections(21.3%) | Pneumonia(20.6%) | Surgical site infections(17.4%) | E.coli(10.5%) | Enterococcus species(13.1%) | Pseudomonas aeroginosa(11.4%) |
| Ireland [[49](#_ENREF_49)] | HI | Roche et al., 2016 | 24 LTCFs | Period | ECDC & HPSC | May 2013 | 46/1060(4.3%) | Respiratory tract infections(35.0%) | Skin infections(35.0%) | Urinary tract infections(12.0%) | - | - | - |
| Slovakia [[50](#_ENREF_50)] | HI | Stefkovicova et al., 2015 | 40 hospital | Period | ECDC | June 2012 | 298/8397(3.5%) | Urinary tract infections(26.2%) | Surgical site infections(15.7%) | Blood stream infections (9.9%) | E.coli.(15.0%) | Klebsiella species(12.5%) | Pseudomonas aeroginosa(10.8%) |
| France [[51](#_ENREF_51)] | HI | Milliani et al.,2015 | 4 HCS | Period | France National PPS | 14 May- 21 June 2012 | 403/5954(6.8%) | Urinary tract infections(26.6%) | Skin and soft tissue infections(17.6%) | Surgical site infections(15.0%) | Enterobacteiaceae(41.0%) | Gram positive cocci(40.0%) | Stapgylococcus aureus(21.0%) |
| 19 Countries [[53](#_ENREF_53)] | HI | Katrien et al., 2014 | 1181 LTCFs | Period | ECDC | April-May 2013 | 2626/77264(3.4%) | Respiratory tract infections(31.2%) | Urinary tract infections(31.2%) | Skin infections(22.8%) | E. coli(34.4%) | Staphylococcus aureus(10.2%) | Proteus Mirabilis(8.1%) |
| 28 Countries [[52](#_ENREF_52)] | HI | Katrien et al., 2014 | 722 LCTF | Period | ECDC | May- September 2010 | 2495/61932(4.0%) | Respiratory tract infections(33.6%) | Urinary tract infections(22.3%) | Skin infections(21.4%) | E.coli(38.3%) | Staphylococcus aureus(13.5%) | Proteus mirabilis(9.9%) |
| 12 Countries [[54](#_ENREF_54)] | HI | Erdam et al., 2014 | 88 ICUs | One day | CDC | Between June- July 2012 /one day | 305/749(40.7%) | Pneumonia(53.4%) | Bloodstream infections(18.3%) | Urinary tract infections(30.7%) | Gram negative bacilli(20.3%) | Acinetobacter species(15.4%) | Pseudomonas aeruginosa(9.5%) |
| Italy [[55](#_ENREF_55)] | HI | Sinatra et al., 2013 | 3 departments | One day | ECDC | September 2011 | 12/328(3.6%) | Blood stream infections(50.0%) | Urinary tract infections(28.5%) | - | - | - | - |
| Ireland [[56](#_ENREF_56)] | HI | Smiddy et al., 2013 | 8 units | Period | Own | 2006-2009 | 23/754(3.0%) | Bloodstream infections(25.0%) | Surgical site infections(25.0%) | Urinary tract infections(20.8%) | - | - | - |
| Germany [[57](#_ENREF_57)] | HI | Behnke et al., 2013 | 132 hospitals | Period | ECDC | September- October 2011 | 2109/41539(5.1%) | Surgical site infections(24.3%) | Urinary tract infections(23.2%) | Respiratory tract infections(21.7%) | E.coli(18.0%) | Enterococci(13.2%) | Staphylococcus aureus(13.1%) |
| 33 Countries [[58](#_ENREF_58)] | HI | Carl Suetens et al.,2013 | 947 hospitals | Period | ECDC | 2011-2012 | 13829/231459(5.9%) | Respiratory tract infections(23.5%) | Surgical site infections(19.6%) | Urinary tract infections(19.0%) | E. coli(15.9%) | Staphylococcus aureus(12.3%) | Enterococcus species(9.6%) |
| 23 Countries [[13](#_ENREF_13)] | HI | Zarb et al., 2012 | 66 hospitals | Period | ECDC | May 2010- October 2010 | 1408/19888(7.0%) | Pneumonia(25.7%) | Surgical site infections(18.9%) | Urinary tract infections(17.2%) | E. coli(15.2%) | Staphylococcus aureus(12.1%) | Pseudomonas aeroginosa(11.2%) |
| Germany [[59](#_ENREF_59)] | HI | Heudorf et al.,2012 | 40 nursing homes | Period | HALT | January 5,- Mach 9, 2011  | 161/3732(4.3%) | Urinary tract infections(28.0%) | Respiratory tract infections(25.5%) | Skin infections(15.5%) | - | - | - |
| London [[60](#_ENREF_60)] | HI | Coello et al., 2011 | 5 hospitals | Period | ESAC | July 2009 | 104/1354(7.7%) | Surgical site infections(18.2%) | Urinary tract infections(18.2%) | Bloodstream infections(14.0%) | - | - | - |
| France [[61](#_ENREF_61)] | HI | Lietard et al., 2011 | 2337 healthcare facilities | One day | CDC | 2006 | 12182/199716(6.1%) | Urinary tract infections(2.4%) | Pneumonia(2.4%) | Surgical site infections(0.8%) | E.coli(28%) | Staphylococcus aureus(18.2%) | Pseudomonas aeruginosa(9.5%) |
| Greece [[62](#_ENREF_62)] | HI | Alexopoulos et al., 2011 | 6 hospitals | One day | CDC | December 2005- February 2006 | 64/2180(2.9%) | Urinary tract infections(34.2%) | Lower respiratory tract infections(14.3%) | Bloodstream infections(14.3%) | E. coli(14.3%) | Pseudomonas areuginosa(10%) | Enterococcus species(8.6%) |
| England [[63](#_ENREF_63)] | HI | Hopkins et al., 2011 | 103 organization | Period | ECDC | September-November 2011 | 3360/52443(6.4%) | Respiratory tract infections(22.8%) | Urinary tract infections(17.2%) | Surgical site infections(15.7%) | Enterobacteriaciae(14.1%) | Staphylococcus aureus(6.7%) | Closridium difficile(5.4%) |
| Scotland [[64](#_ENREF_64)] | HI | Cairns et al., 2011 | 45 hospital | Period | CDC | 2005-2006 | 1094/11090 (9.8%) | Urinary tract infections(17.9%) | Surgical site infections(15.7%) | Gastrointestinal infections(15.5%) | - | - | - |
| Scotland [[65](#_ENREF_65)] | HI | Cairns et al., 2010 | 29 ICUs | Period | Own | October 2005-September 2006 | 35/129(27.1%) | Lower respiratory tract infections(23.9%) | Surgical site infections(23.9%) | Pneumonia(19.5%) | - | - | - |
| Belgium [[66](#_ENREF_66)] | HI | Gordts et al., 2010 | 63 hospitals | Period | CDC | October – November 2007 | 1037/17343(5.9%) | Urinary tract infections(23.9%) | Lower respiratory tract infections(20.0%) | Surgical site infections(14.6%) | - | - | - |
| Italy [[67](#_ENREF_67)] | HI | Lanini et al., 2009 | 51 hospitals | Period | CDC | 2002-2004 | 589/9609(6.1%) | Lower respiratory tract infections(35.8%) | Urinary tract infections(23.6%) | Bloodstream infections(14.0%) | Gram negative bacteria(52.7%) | Gram positive bacteria(38.8%) | Fungi(5.0%) |
| 75 Countries [[68](#_ENREF_68)] | HI | Vincet et al., 2009 | 1265 ICUs | One day | CDC | 2006-2007 | 7087/13796(51.3%) | Respiratory tract infections(63.5%) | Abdominal infections(19.6%) | Bloodstream infections(15.0%) | Staphylococcus aureus(20.5%) | E .coli(16.0%) | Pseudomonas species(19.9%) |
| France [[69](#_ENREF_69)] | HI | Patte et al., 2005 | Homecare Setting (HCS) | One day | Own | June 5, 2000 | 23/376(6.1%) | Urinary Tract Infections(50.0%) | Skin Infections(37.9%) | - | E. coli(29.4%) | Staphylococcus aureus(29.4%) | Enterococcus species(17.6%) |
| Italy [[70](#_ENREF_70)] | HI | Lizioli et al., 2003 | 88 hospitals | Period | Own | February-March 2000 | 916/18667(4.9%) | Urinary tract infections(33.6%) | Pneumonia(22.6%) | Surgical site infections(15.0%) | E.coli(16.8%) | Staphylococcus aureus(15.0%) | Pseudomonas aeruginosa(13.2%) |
| Greece [[71](#_ENREF_71)] | HI | Starakis et al., 2002 | 19 units | Period | CDC | 1998 and 1999 | 97/997(9.7%) | Lower respiratory tract infections(36.0%) | Urinary tract infections(25.8%) | Bloodstream infections(19.6%) | Pseudomonas aeroginosa(20.6%) | Kelbsiella pneumonia(8.2%) | Staphylococcus (7.2%) |
| Greece [[72](#_ENREF_72)] | HI | Gikas et al., 2002 | 14 hospitals | One day | CDC | November 16, 1999 | 337/3925(8.6%) | Lower respiratory tract infections(30.3%) | Urinary tract infections(22.7%) | Bloodstream infections(15.8%) | Pseudomonas aeroginosa(16.6%) | E. coli(10.8%) | Klebsiella pneumoniae(10.3%) |
| France [[73](#_ENREF_73)] | HI | Group et al., 2000 | 830 hospitals | Period | Own | May 20 - June 21 1996 | 15798/236334(6.7%) | Urinary tract infections(0.19%) | Lower respiratory tract infections(0.07%) | Surgical site infections(0.06%) | E. coli(20%) | Staphylococcus aureus(16%) | Pseudomonas aeroginosa(11%) |
| Switzerland [[74](#_ENREF_74)] | HI | Pittet et al., 1999 | 4 hospitals | One week | CDC | May 1996  | 156/1349(11.6%) | Surgical site infections(30.0%) | Urinary tract infections(22.0%) | Respiratory tract infections(15.0%) | Enterobacteriaceae(28.0%) | Staphylococcus aureus(13.0%) | Pseudomonas aeruginosa(11.0%) |
| 17 Countries [[75](#_ENREF_75)] | HI | Vincent et al., 1995 | 1417 ICUs | One day | Own | April 28-April 29, 1992 | 4501/10038(44.8%) | Pneumonia(46.9%) | Lower respiratory tract infections(17.8%) | Urinary tract infections(17.6%) | Enterobacteriaceae(34.4%) | Staphylococcus aureus(30.1%) | Pseudomonas aeroginosa(28.7%) |
| **ASIA** |  |  |  |  |  |  |  |  |  |  |  |  |  |
| China [[76](#_ENREF_76)] | UMI | Chen et al.,2017 | 52 hospitals | One day | NHFPC | October 2014-March 2015 | 1998/53939(3.7%) | Lower respiratory tract infections(47.2%) | Urinary tract infections(12.3%) | Upper respiratory tract infections(11.0%) | Pseudomonas aeroginosa(9.4%) | AcinetobacterBaumanni(7.9%) | Klebsiellapnuemoniae(7.3%) |
| India [[77](#_ENREF_77)] | LMI | Nair et al., 2017 | 1 hospital | Period  | CDC | March 2014-August 2014 | 71/1886(3.7%) | Surgical site infections(23.9%) | Pneumonia (18.3%) | Upper respiratory tract infections(16.9%) | - | - | - |
| Singapore [[78](#_ENREF_78)] | HI | Cai et al., 2017 | 13 hospitals | Period | ECDC | July 2015- February 2016 | 646/5415(11.9%) | Clinical sepsis(25.5%) | Pneumonia(24.8%) | - | Staphylococcus aureus(12.9%) | Pseudomonas aeroginosa(11.5%) | - |
| China [[79](#_ENREF_79)] | UMI | Liu et al.,2016 | 124 hospitals  | One day | BNICC | May 2014 | 1294/61990(2.0%) | Urinary tract infections(15.0%) | Gastrointestinal infections(7.7%) | Surgical site infections(6.3%) | Pseudomonas aeruginosa(13.8%) | Acinetobacterbaumannii(12.9%) | E.Coli(12.6%) |
| China [[80](#_ENREF_80)] | UMI | Zhang et al., 2016 | 43 clinical departments | Period | CDC | May 2012-May 2014 | 147/4029(3.6%) | Respiratory tract infections(54.8%) | Urinary tract infections(21.4%) | Blood stream infections(7.1%) | Gram negative bacteria(67.1%) | Gram positive bacteria(20.3%) | Fungi(10.5%) |
| Vietnam [[81](#_ENREF_81)] | LMI | Phu et al., 2016 | 14 ICUs | One day each month | ECDC | October 2012- October 2013 | 965/3266(29.5%) | Lower respiratory tract infections and pneumonia(79.4%) | Bloodstream infections(4.4%) | Surgical site infections(4.2%) | Acinetobacter baumannii(24.4%) | Pseudomonas aeroginosa(13.8%) | Klebsiella pneumoniae(11.6%) |
| Japan [[82](#_ENREF_82)] | HI | Morioka et al.,2015 | 1 Hospital | One day | ECDC | July 3, 2014 | 85/841(10.1%) | Pneumonia (20.0%) | Surgical site infections(19.0%) | Blood stream infections (11.1%) | Enterobacteriaceae(27.6%) | Staphylococcus aureus(15.5%) | Enterococcuss(10.3%) |
| India [[83](#_ENREF_83)] | LMI | Kumar et al., 2014 | 1 Hospital | One day | CDC | 2008 and 2011 | 125/1834(6.8%) | Surgical site infections(33.0%) | Upper respiratory tract infections(26.0%) | Pneumonia(24.0%) | Klebsiella pneumonia(15.0%) | Pseudomonas aeruginosa(15.0%) | Acinetobactercalcobaumanni(2.4%) |
| China [[84](#_ENREF_84)] | UMI | Tao et al., 2014 | 48 wards | One day | US CDC | November 13,2013 | 86/2434(3.5%) | Respiratory tract infections(49.4%) | Surgical Site infections(22.9%) | Gastrointestinal infections(9.2%) | Pseudomonas aeruginosa(24.0%) | Klebseilla pneumonia(14.0%) | E. coli(14.0%) |
| China [[85](#_ENREF_85)] | UMI | Xie et al., 2013 | 5 departments | Period | NISS | 2007-2011 | 287/9533(3.0%) | Respiratory tract infections(74.1%) | Urinary tract infections(8.9%) | Surgical site infections(5.9%) | Pseudomonas aeruginosa(10.4%) | E.coli(5.9%) | Acinetobacter baumannii(5.9%) |
| Iran [[86](#_ENREF_86)] | UMI | Askarian et al., 2012  | 8 hospitals | Period | NNIS | 2008-2009 | 323/3450(9.4%) | Bloodstream infections(26.6%) | Surgical site infections(25.7%) | Urinary tract infections(14.9%) | - | - | - |
| Vietnam [[87](#_ENREF_87)] | LMI | Thu et al., 2011 | 36 hospitals | Period | CDC | February 2008- December 2009 | 553/7571(7.3%) | Pneumonia(41.9%) | Surgical site infections(27.5%) | - | Pseudomonas aeruginosa(31.5%) | Acinetobacterbaumannii(23.3%) | - |
| Mongolia[[88](#_ENREF_88)] | LMI | Ider et al., 2010 | 2 hospitals | One day | US CDC | September 2008 | 50/933(5.3%) | Respiratory tract infections(24%) | Urinary tract infections(20%) | Surgical site infections(20%) | - | - | - |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| China [[12](#_ENREF_12)] | UMI | Xie et al., 2010 | 13 hospitals | Period | CDC | November, 2007-November, 2008 | 790/20350(3.9%) | Respiratory tract infections(63.1%) | Surgical site infections(9.6%) | Urinary tract infections(8.6%) | Pseudomonas aeruginosa(16.4%) | E.coli(10.5%) | Klebsiella pneumoniae (7.9%) |
| Hong Kong [[89](#_ENREF_89)] | HI | Lee et al., 2007 | 1 hospital | One day | CDC | September 7,2005 | 41/1021(4.0%) | Pneumonia(33%) | Surgical site infections(26.2%) | Bloodstream infections(21.4%) | Pseudomonas aeroginosa(N/A) | Staphylococcus aureus(N/A) | - |
| Saudi Arabia [[90](#_ENREF_90)] | HI | Balkhy et al., 2006 | 7 units | One day | Own | May 2003 | 38/562(6.7%) | Bloodstream infections(31.1%) | Ventilator acquired pneumonia(28.9%) | Urinary tract infections(24.4%) | Pseudomonas species(20.9%) | Enterococcuss species(18.9%) | Klebsiella pneumoniae(13.7%) |
| Thailand [[91](#_ENREF_91)] | LMI | Danchaivijitret al., 2005 | 42 hospitals | Two week | Own | March 12- March 25 2001 | 1181/18456(6.4%) | Lower respiratory tract infections(34.0%) | Urinary tract infections(21.5%) | Surgical site infections(15.0%) | Pseudomonas aeruginosa(19.8%) | Klebsiella pneumonia(13.5%) | Acinetobacter species(13.0%) |
| Malaysia [[92](#_ENREF_92)] | UMI | Hughes et al., 2005 | 5 clinical departments | Period | CDC | July 16-17, 2001 | 75/538(13.9%) | Clinical sepsis(22.4%) | Pneumonia(21.4%) | Urinary tract infections(12.2%) | Pseudomonas aeruginosa(17.4%) | MRSA(15.5%) | MSSA(8.7%) |
| Turkey [[93](#_ENREF_93)] | UMI | Esen et al., 2004 | 56 ICUs | One day | CDC | September 19, 2001 | 115/236(48.7%) | Pneumonia(28.0%) | Blood stream infections(23.3%) | Urinary tract infections(15.7%) | Pseudomonas aeroginosa(20.8%) | Staphylococcus aureus(18.2%) | Acinetobacter species (18.2%) |
| **AMERICAs** |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Canada [[106](#_ENREF_106)] | HI | Taylor et al., 2016 | 49 hospitals | One day | NHSN | February 2009 | 1173/9953(11.7%) | Urinary tract infections(34.8%) | Pneumonia(21.8%) | Surgical site Infections(17.4%) | - | - | - |
| Florida [[95](#_ENREF_95)] | HI | Magill et al., 2012 | 9 hospitals | One day | NHSN | August 2009 | 51/851(6.0%) | Surgical site infections(31.0%) | Pneumonia(15.5%) | Urinary tract infections(15.5%) | Staphylococcus aureus(15.5%) | Candida species(10.3%) | Pseudomonas aeruginosa(8.6%) |
| USA [[96](#_ENREF_96)] | HI | Magill et al., 2014 | 183 hospitals | One day | NHSN | May-September 2011 | 452/11282(4.0%) | Pneumonia(21.8%) | Surgical site infections(21.8%) | Gastrointestinal infections(17.1%) | Clostridium difficile(12.1%) | Staphylococcus aureus(10.7%) | Klebsiella pneumonia(9.9%) |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Canada [[97](#_ENREF_97)] | HI | Gravel et al., 2007 | 25 hospitals | Period | CDC | February 5 – February 8 2001 | 601/5750(10.4%) | Urinary tract infections(3.4%) | Pneumonia(3.0%) | Surgical site infections(2.5%) | Coagulase negative staphylococcus(N/A) | Gram negative bacteria(N/A) | Gram positive bacteria(N/A) |
| Brazil [[98](#_ENREF_98)] | UMI | Rezende et al., 1998 | 11 hospitals | Period | CDC & NNIS | August – October 1992 | 267/ 2339(11.4%) | Pneumonia(19.5%) | Surgical site infections(19.2%) | Urinary tract infections(13.1%) | Staphylococcus aureus(21.6%) | E.coli(21.6%) | Pseudomonas species(12.5%) |
| **AFRICA** |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Ethiopia [[99](#_ENREF_99)] | LI | Yallew et al., 2016 | 2 hospitals | Period | CDC | March- July 2015 | 135/908(14.8%) | Surgical site infections(51.1%) | Pneumonia(25.0%) | Blood stream infections(19.0%) | Klebseilla species(22.4%) | Staphylococcus aureus(20.4%) | Pseudomonas aeruginosa(18.3%) |
| Tunisia [[100](#_ENREF_100)] | LMI | Kallel et al., 2005 | 15 departments | One day | Own | April 17-april 18 2002 | 50/280(14.3%) | Pneumonia(32.0%) | Surgical site infections(28.0%) | Urinary tract infections(20.0%) | Klebsiella pneumoniae(23.1%) | Pseudomonas aeroginosa(19.2%) | Acinetobacterbaumannii(15.4%) |
| \*Percentages of total infections, E.coli= Escherichia coli, N/A= Not Available, LMI= low middle income and low income country, HI= High Income country, UMI= Upper middle income country, CDC= Centre for Disease Prevention and Control, ECDC= European Centre for Disease Prevention and Control, NHSN= National Healthcare Safety Network, HELICS= Hospital in Europe Link for Infection Control through Surveillance, EU-PPS-AU= Europe Union Point Prevalence Surveys and Antibiotic Use Protocol, HPSC= Health Protection Surveillance Centre, HALT= Healthcare associated infections in Long Term care Facilities project, ESAC= European Surveillance of Antibiotic consumption, NHFPC= National Health and Family Planning Commission Centre, BNICC= Beijing Nosocomial infection Surveillance system,  |

|  |
| --- |
| **TABLE 2.** Point Prevalence Surveys in Pediatrics |
| **Continent and Countries** | **World** **Bank Classification** | **Author Name and Date** | **Settings** | **PPS Method** | **PPS Protocol** | **Study Duration** | **HAIs****(%)\*** | **Top Three Types of Infections****(%)\*** | **Top Three types of microorganisms****(%)** |
| **EUROPE** |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 29 Countries [[101](#_ENREF_101)] | HI | Zingget al.,2017 | 1149 hospitals | Period | ECDC | May 2011-November 2012 | 726/17273(4.2%) | Bloodstream infections(45%) | Lower respiratory infections(22.0%) | Gastronintestinal infection(8.0%) | Enterobacteriacea(15.0%) | - | - |
| Russia [[102](#_ENREF_102)] | UMI | Hajdu et al., 2007 | 1 hospital | One day | HELICS | February 2006 | 60/395(15.1%) | Upper respiratory tract infections(45.0%) | Lower respiratory tract infections(19.0%) | Urinary tract infections(12.0%) | - | - | - |
| **ASIA** |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Vietnam [[103](#_ENREF_103)] | LMI | Le et al., 2016 | ICUs | One day/once in a month | ECDC | October 2012- September 2013 | 454/1363(33.3%) | Pneumonia(65.2%) | Blood stream infections(26.1%) | Surgical site infections(2.0%) | Klebseilla pneumonia(19.0%) | Pseudomonas species(18.0%) | Acinetobacter species(15.0%) |
| Turkey [[14](#_ENREF_14)] | UMI | Kepenekliet al., 2015 | 50 ICUs | One day | CDC | September 2012 | 122/327(37.3%) | Lower respiratory tract infections(55.3%) | Blood stream infections(27.3%) | Urinary tract infections(7.1%) | Pseudomonas aeruginosa(24.0%) | Acinetobacter species(15.0%) | Candida species(7.0%) |
| **AMERICA** |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Canada [[94](#_ENREF_94)] | HI | Rutledge-Taylor et al., 2012 | 30 hospitals | One day | CDC | February 3, 2009 | 118/1353(8.7%) | Bloodstream infections(30.6%) | Pneumonia(16.1%) | Viral gastroenteritis(13.7%) | Coagulase negative staphylococcus(47.4%) | Pseudomonas aeroginosa(35.0%) | Candida species(30.8%) |
| Canada [[11](#_ENREF_11)] | HI | Gravel et al., 2007 | 25 hospitals | One day | CNISP | February 5 – February 8 2001 | 80/997(8.0%) | Blood stream infections(37.5%) | Pneumonia(26.2%) | Urinary tract infections(12.5%) | Coagulase negative staphylococcus(NA) | Gram negative bacteria(NA) | Gram positive bacteria(NA) |
| US [[104](#_ENREF_104)] | HI | Grohskopfet al., 2002 | 31 hospitals | One day | Own | August 1999 | 61/512(11.9%) | Bloodstream infections(41.3%) | Respiratory tract infections(22.6%) | Urinary tract infections(13.3%) | Coagulase negative staphylococcus(19.5%) | Enterococcus(12.2%) | Staphylococcus aureus(11.0%) |
| US [[105](#_ENREF_105)] | HI | Sohn et al., 2001 | 29 Neonatal intensive care units | One day | Own | August 9, 2000 | 94/827(11.3%) | Bloodstream infections(52.6%) | Respiratory tract infections(12.9%) | Urinary tract infections(8.6%) | Coagulase negative staphylococcus(31.6%) | Enterococci(10.3%) | E.coli(8.5%) |
| \*Percentages of total infections, E.coli= Escherichia coli, N/A= Not Available, LMI= low and low middle income country, HI= High Income country, UMI= Upper middle income country, , CDC= Centre for Disease Prevention and Control, ECDC= European Centre for Disease Prevention and Control, HELICS= Hospital in Europe Link for Infection Control through Surveillance, CNISP= Canadian Nosocomial Infection Surveillance Programs |

|  |
| --- |
| **Table 3.** Quality assessment of included articles  |
|  | **Selection** | **Comparability** | **Outcomes** |  |
| **Studies** | **Representatives of sampleA** | **Sample sizeB** | **Non-respondentsC** | **Ascertainment of exposureD** | **Based on design and analysisE** | **Assessment of outcomesF** | **Statistical testG** | **Quality score** |
| Deptula et al., 2017 [[44](#_ENREF_44)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Sticchi et al.,2017 [[45](#_ENREF_45)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Swissnoso, 2017 [[46](#_ENREF_46)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Klavs et al., 2016 [[47](#_ENREF_47)] | \* | \* | - | \*\* | \* | \*\* | \* | 8 |
| Lusignani et al., 2016 [[48](#_ENREF_48)] | \* | \* | - | \* | \*\* | \*\* | - | 7 |
| Roche et al., 2016 [[49](#_ENREF_49)] | \* | \* | - | \* | \* | \*\* | - | 6 |
| Stefkovicova et al., 2015 [[50](#_ENREF_50)] | \* | \* | - | \* | \*\* | \*\* | - | 7 |
| Milliani et al.,2015 [[51](#_ENREF_51)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Katrien et al., 2014[[53](#_ENREF_53)] | \* | \* | - | \*\* | \*\* | \*\* | - | 8 |
| Katrien et al., 2014[[52](#_ENREF_52)] | \* | \* | - | \*\* | \*\* | \*\* | \* | 9 |
| Erdam et al., 2014[[54](#_ENREF_54)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Sinatra et al., 2013 [[55](#_ENREF_55)] | \* | \* | - | \* | \* | \*\* | \* | 7 |
| Smiddy et al., 2013 [[56](#_ENREF_56)] | \* | \* | - | \* | \* | \*\* | \* | 7 |
| Behnke et al., 2013 [[57](#_ENREF_57)] | \* | \* | - | \*\* | \*\* | \*\* | \* | 9 |
| Carl Suetens et al.,2013[[58](#_ENREF_58)] | \* | \* | - | \*\* | \*\* | \*\* | \* | 9 |
| Zarb et al., 2012[[13](#_ENREF_13)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Heudorf et al.,2012 [[59](#_ENREF_59)] | \* | \* | - | \* | \* | \*\* | \* | 7 |
| Coello et al., 2011 [[60](#_ENREF_60)] | \* | \* | - | \* | \* | \*\* | - | 6 |
| Lietard et al., 2011 [[61](#_ENREF_61)] | \* | \* | - | \* | \*\* | \*\* | - | 7 |
| Alexopoulos et al., 2011 [[62](#_ENREF_62)] | \* | \* | - | \* | \*\* | \*\* | - | 7 |
| Hopkins et al., 2011 [[63](#_ENREF_63)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Cairns et al., 2011 [[64](#_ENREF_64)] | \* | \* | - | \* | \* | \*\* | \* | 7 |
| Cairns et al., 2010 [[65](#_ENREF_65)] | \* | \* | - | \* | \* | \*\* | \* | 7 |
| Gordts et al., 2010 [[66](#_ENREF_66)] | \* | \* | - | \*\* | \* | \*\* | \* | 8 |
| Lanini et al., 2009 [[67](#_ENREF_67)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Vincet et al., 2009[[68](#_ENREF_68)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Patte et al., 2005 [[69](#_ENREF_69)] | \* | \* | - | \* | \* | \*\* | \* | 7 |
| Lizioli et al., 2003 [[70](#_ENREF_70)] | \* | \* | - | \* | \*\* | \*\* | - | 7 |
| Starakis et al., 2002 [[71](#_ENREF_71)] | \* | \* | - | \* | \*\* | \*\* | - | 7 |
| Gikas et al., 2002[[72](#_ENREF_72)] | \* | \* | - | \*\* | \* | \*\* | \* | 9 |
| Group et al., 2000 [[73](#_ENREF_73)] | \* | \* | - | \*\* | \*\* | \*\* | \* | 9 |
| Pittet et al., 1999[[74](#_ENREF_74)] | \* | \* | - | \*\* | \*\* | \*\* | \* | 9 |
| Vincent et al., 1995[[75](#_ENREF_75)] | \* | \* | - | \*\* | \*\* | \*\* | - | 8 |
| Chen et al.,2017 [[76](#_ENREF_76)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Nair et al., 2017 [[77](#_ENREF_77)] | \* | \* | - | \*\* | \* | \*\* | \* | 8 |
| Cai et al., 2017 [[78](#_ENREF_78)] | \* | \* | - | \* | \* | \*\* | \* | 7 |
| Liu et al.,2016 [[79](#_ENREF_79)] | \* | \* | - | \*\* | \*\* | \*\* | \* | 9 |
| Zhang et al., 2016 [[80](#_ENREF_80)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Phu et al., 2016 [[81](#_ENREF_81)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Morioka et al.,2015 [[82](#_ENREF_82)] | \* | \* | - | \*\* | \*\* | \*\* | \* | 9 |
| Kumar et al., 2014 [[83](#_ENREF_83)] | \* | \* | - | \* | \*\* | \*\* | - | 7 |
| Tao et al., 2014 [[84](#_ENREF_84)] | \* | \* | - | \*\* | \*\* | \*\* | \* | 9 |
| Xie et al., 2013 [[85](#_ENREF_85)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Askarian et al., 2012 [[86](#_ENREF_86)] | \* | \* | - | \* | \* | \*\* | \* | 7 |
| Thu et al., 2011 [[87](#_ENREF_87)] | \* | \* | - | \*\* | \* | \*\* | \* | 8 |
| Ider et al., 2010[[88](#_ENREF_88)] | \* | \* | - | \* | \* | \*\* | \* | 7 |
| Xie et al., 2010[[12](#_ENREF_12)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Lee et al., 2007[[89](#_ENREF_89)] | \* | \* | - | \* | \* | \*\* | \* | 7 |
| Balkhy et al., 2006[[90](#_ENREF_90)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Danchaivijitret al., 2005 [[91](#_ENREF_91)] | \* | \* | - | \* | \*\* | \*\* | - | 7 |
| Hughes et al., 2005 [[92](#_ENREF_92)] | \* | \* | - | \*\* | \*\* | \*\* | \* | 9 |
| Esen et al., 2004 [[93](#_ENREF_93)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Taylor et al., 2016 [[106](#_ENREF_106)] | \* | \* | - | \* | \* | \*\* | \* | 7 |
| Magill et al., 2012 [[95](#_ENREF_95)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Magill et al., 2014 [[96](#_ENREF_96)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Gravel et al., 2007[[97](#_ENREF_97)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Rezende et al., 1998 [[98](#_ENREF_98)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Yallew et al., 2016 [[99](#_ENREF_99)] | \* | \* | - | \*\* | \*\* | \*\* | \* | 9 |
| Kallel et al., 2005 [[100](#_ENREF_100)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Zingg et al.,2017[[101](#_ENREF_101)] | \* | \* | - | \* | \* | \*\* | \* | 7 |
| Hajdu et al., 2007 [[102](#_ENREF_102)] | \* | \* | - | \* | \* | \*\* | \* | 7 |
| Le et al., 2016 [[103](#_ENREF_103)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Kepenekli et al., 2015 [[14](#_ENREF_14)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Rutledge-Taylor et al., 2012 [[94](#_ENREF_94)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Gravel et al., 2007[[11](#_ENREF_11)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Grohskopf et al., 2002 [[104](#_ENREF_104)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| Sohn et al., 2001 [[105](#_ENREF_105)] | \* | \* | - | \* | \*\* | \*\* | \* | 8 |
| A: \*= truly representative of average in target population or somewhat representative of average in target populationB: \*=justified or satisfactory, -- = not justifiedC: \*=satisfactory response rate, --= unsatisfactory or no descriptionD: \*\*=validated measurement tool, \*=non validated measurement tool, --= no description of measurement toolE: \*\*=confounding factors, \*incomplete information, --= no informationF: \*\*=independent blinded assessment or record linkage, \*=self-report, --= no descriptionG: \*=Yes, --=No |



**Figure 1.** Flow chart and selection strategies of studies.